[Table_MainInfo] 公司研究/有色金属/其他有色金属 证券研究报告 赤峰黄金（600988）公司半年报点评 2024 年 09 月 03 日 [Table_InvestInfo] 投资评级 优于大市 维持 | --- | --- | |-----------------------------------------------------|-------------| | 股票数据 | | | 0 [ 9 Table_StockInfo 月 02 日收盘价（元） ] | 17.00 | | 52 周股价波动（元） | 11.23-21.57 | | 总股本 / 流通 A 股（百万股） | 1664/1664 | | 总市值 / 流通市值（百万元） | 28286/28286 | | 相关研究 | | | [Table_ReportInfo] 《赤峰黄金：降本增效成果显著》 | 2024.04.01 | | 《赤峰黄金：短期因素影响公司三季度业绩， | | | 溪灯坪金矿正式投产》 2023.10.31 | | 市场表现 [Table_QuoteInfo] -23.12% -11.12% 0.8 ...

[Table_MainInfo] 公司研究/机械工业/其他专用机械 证券研究报告 宏华数科（688789）公司半年报点评 2024 年 09 月 03 日 [Table_InvestInfo] 投资评级 优于大市 维持 | --- | --- | |----------------------------------------------------------------|--------------| | 股票数据 | | | 09 [ Table_StockInfo 月 02 日收盘价（元） ] | 62.78 | | 52 周股价波动（元） | 55.50-122.29 | | 总股本 / 流通 A 股（百万股） | 179/179 | | 总市值 / 流通市值（百万元） | 11266/11266 | | 相关研究 | | | [Table_ReportInfo] 《设备 + 耗材销量上行加速，非纺业务突破打 | | | 开成长空间》 2024.06.03 | | | 《数码喷印设备翘楚，全产业链优势 | + 应用拓 | | 展打开成长空间》 2024.03.14 | | 市场表现 [Table_ ...

Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [1] Core Views - The company's proprietary business has shown outstanding performance, driving overall profit growth, while brokerage, asset management, and investment banking businesses have experienced declines. The report remains optimistic about the company's collaboration with China Merchants Group and China Merchants Bank, with a reasonable value range set at 15.76-17.07 yuan, maintaining the "Outperform the Market" rating [5] Summary by Sections Financial Performance - In the first half of 2024, the company achieved operating revenue of 9.6 billion yuan, a year-on-year decrease of 11.1%, and a net profit attributable to shareholders of 4.75 billion yuan, a slight increase of 0.4%. The corresponding EPS is 0.51 yuan, with an ROE of 4.1%, down 0.3 percentage points year-on-year. The second quarter saw operating revenue of 5.3 billion yuan, down 12.2% year-on-year but up 23.2% quarter-on-quarter, and a net profit of 2.59 billion yuan, up 5.0% year-on-year and 20.1% quarter-on-quarter [5] Business Segments - Brokerage business revenue in the first half of 2024 was 2.58 billion yuan, down 12.1% year-on-year, accounting for 27.0% of total revenue. The average daily trading volume in the market was 961.6 billion yuan, down 6.4% year-on-year. The company is enhancing the professional capabilities of its wealth advisory team and optimizing the empowerment system for wealth advisors to improve client service quality [5] - Investment banking revenue in the first half of 2024 was 280 million yuan, down 36.3% year-on-year. The underwriting scale for equity business increased by 45.8% year-on-year, while bond underwriting scale rose by 35.8% year-on-year. The company ranked fifth in equity underwriting scale, with a total of 11.97 billion yuan in equity underwriting, including 3.5 billion yuan from IPOs and 8.4 billion yuan from refinancing [5] - Asset management revenue was 340 million yuan, down 8.5% year-on-year, with total asset management scale reaching 302.2 billion yuan, up 2.5% year-on-year [5] Investment Strategy - The company achieved positive growth in proprietary investments, with investment income (including fair value) of 4.75 billion yuan in the first half of 2024, up 21.3% year-on-year. The second quarter's investment income was 2.7 billion yuan, up 23.3% year-on-year. The company continues to implement a "large and stable" investment strategy, adjusting and optimizing the investment structure according to market conditions [5] Earnings Forecast - The company expects EPS for 2024-2026 to be 0.99, 1.20, and 1.28 yuan respectively, with BVPS of 13.13, 13.99, and 15.01 yuan respectively. A P/B ratio of 1.2-1.3x is assigned for 2024, corresponding to a reasonable value range of 15.76-17.07 yuan, maintaining the "Outperform the Market" rating [5]

[Table_MainInfo] 公司研究/机械工业/电气设备 证券研究报告 泰胜风能（300129）公司半年报点评 2024 年 09 月 03 日 Email:wj10521@haitong.com 证书:S0850515120001 分析师:徐柏乔 Tel:(021)23219171 Email:xbq6583@haitong.com 证书:S0850513090008 联系人:马菁菁 [Table_InvestInfo] 投资评级 优于大市 维持 | --- | |-----------------------------------------------------------------------| | 股票数据 | | 09 [ Table_StockInfo 月 02 日收盘价（元） ] | | 52 周股价波动（元） | | 总股本 / 流通 A 股（百万股） | | 总市值 / 流通市值（百万元） | | 相关研究 | | [Table_ReportInfo] 《 24Q1 海外订单新增 5.22 亿元，同比大增》 | | 2024.05.12 | | 《 2023Q3 归母净利润 1 ...

[Table_MainInfo]行业研究/农业 证券研究报告 行业周报 2024 年 09 月 03 日 [Table_InvestInfo] 投资评级 优于大市 维持 [Table_AuthorInfo] 市场表现 [Table_QuoteInfo] 农业 海通综指 -22.60% -17.18% -11.75% -6.32% -0.90% 4.53% 2023/5 2023/8 2023/11 2024/2 资料来源：海通证券研究所 相关研究 [Table_Rep 《景气回升，成本下降，业绩扭亏 ortInfo] 》 2024.08.31 《二育集中出栏导致猪价短期调整，上行 趋势不变》2024.08.26 《猪价高位小幅调整，关注生猪景气窗口 期》2024.08.20 分析师:李淼 Tel:(010)58067998 Email:lm10779@haitong.com 证书:S0850517120001 分析师:冯鹤 Tel:(021)23185702 Email:fh15342@haitong.com 证书:S0850523040003 分析师:巩健 Tel:(021)23185702 Email:g ...

Industry Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [1] Core Views - The pharmaceutical industry is currently at a historical low, with strong demand and stable supply, making it a new quality productive force [2] - Three main investment themes are recommended: innovation, medical device globalization, and state-owned enterprise (SOE) reform [2] Innovation - China's innovation in pharmaceuticals has been upgraded due to policy support and international standards, with key companies to watch including Tigermed, Hengrui Medicine, and CSPC Pharmaceutical Group [2] - From 2018 to 2023, R&D and management expenses increased by 5 percentage points, while sales expenses decreased by 5 percentage points [12] - In 2023, A+H listed pharmaceutical companies had a total revenue of 382.7 billion yuan, with R&D investment accounting for 23% of revenue [12] Medical Device Globalization - Chinese medical device companies are leveraging domestic advantages such as engineering talent and supply chain capabilities to expand globally, with companies like Mindray Medical and New Industries showing significant growth [2] - In 2023, Mindray's overseas revenue exceeded 13.5 billion yuan, a 15.8% increase, while United Imaging Healthcare's overseas revenue grew by 53.9% [24] - The domestic market for medical devices, particularly in aging-related sectors like cardiovascular stents, continues to grow, with PCI surgeries increasing by 26.4% in 2023 [21] State-Owned Enterprise (SOE) Reform - SOE reforms have improved profitability and efficiency, with companies like Taiji Group and Dong-E-E-Jiao showing significant net profit margin growth [33] - Key SOE groups to watch include Sinopharm Group (e.g., Tiantan Biological, Taiji Group) and China Resources Group (e.g., Kunming Pharmaceutical, CR Sanjiu) [2] - SOE reforms have led to increased revenue and reduced costs, with Taiji Group's net profit margin improving from -0.89% in 2019 to 5.46% in 2023 [33] Historical Performance and Market Trends - From 2017 to 2023, the main opportunities in the pharmaceutical sector came from CXO, innovative drugs, and consumer healthcare [4] - The top 20 pharmaceutical companies by market capitalization in 2023 include Mindray Medical, Hengrui Medicine, and WuXi AppTec, with Mindray leading at 352.3 billion yuan [5] - Over the past decade, companies like Mindray and Hengrui have seen significant growth in revenue and market capitalization, with Mindray's revenue increasing from 8 billion yuan in 2015 to 34.6 billion yuan in 2023 [6] Global Pharmaceutical Landscape - Global pharmaceutical giants like Eli Lilly, Novo Nordisk, and Novartis dominate the market, with Eli Lilly leading with a market cap of 860.48 billion USD [9] - Chinese companies like Hengrui Medicine are also making strides globally, with a market cap of 34.42 billion USD and 96% of its revenue coming from China [9] Profitability and R&D Distribution - Large pharmaceutical companies and biotech firms have significantly higher R&D investments compared to smaller companies, with large companies averaging 17.67 billion yuan in R&D investment [15] - Single-product companies like Beta Pharma and Allist Pharmaceuticals have shown that controlling sales and R&D expenses is key to profitability [17] Key Companies and Their Strategies - Mindray Medical has established itself as a global leader in medical devices, with a net profit margin higher than many US-based medical device giants [28] - China Resources Sanjiu has grown through mergers and acquisitions, focusing on consumer health and prescription drugs, with revenue reaching 24.59 billion yuan in 2023 [44]

Investment Rating - The report maintains an "Outperform" rating for the non-ferrous metals industry, indicating an expected return above the benchmark index by more than 10% over the next six months [38]. Core Insights - The industrial and precious metals sectors are showing positive performance, with the aluminum industry achieving new breakthroughs in mid-term dividends [1]. - The copper and aluminum sectors continue to perform well, while energy metals have turned profitable [2]. - There remains a supply shortage in the copper and aluminum sub-sectors [3]. Market Overview - Gold and copper are leading the market, with expectations for the trend to continue [2]. - As of August 30, 2024, the performance of the non-ferrous metals sector has been relatively strong compared to other sectors [4]. Performance Metrics - In Q2 2024, the average prices for LME copper, SHFE aluminum, gold, and silver saw significant increases, with copper rising by 15.7% quarter-on-quarter and silver increasing by 25.3% [7]. - The precious metals sector has benefited from price increases, leading to continued improvement in performance [28]. Sub-sector Analysis - The report highlights ongoing supply shortages in the copper and aluminum sectors, which could impact future pricing and availability [2][3]. - The energy metals sector has shown a turnaround, moving from losses to profitability [2].

[Table_InvestInfo] 投资评级 优于大市 维持 | --- | --- | --- | |---------------------------------------------------------|-------------|-------| | 股票数据 | | | | 0 [ 9 Table_StockInfo 月 02 日收盘价（元） ] | 5.53 | | | 52 周股价波动（元） | 5.12-11.06 | | | 总股本 / 流通 A 股（百万股） | 2752/2571 | | | 总市值 / 流通市值（百万元） | 15219/14219 | | | 相关研究 | | | | [Table_ReportInfo] 《营收稳健增长，销售回款同比高增》 | | | | 2023.09.04 | | | | 市场表现 | | | 华发股份 海通综指 -48.63% -38.63% -28.63% -18.63% -8.63% 2023/9 2023/12 2024/3 2024/6 | --- | --- | --- | --- | |----------------- ...

Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [2][7]. Core Views - The company, Tonghuashun, has a strong advantage in mobile client resources and financial big data cloud computing technology, enabling it to connect B-end to C-end and B-end to B-end, thus building a large internet financial platform. The development of AI investment robots and internet advisory services shows promising prospects. The reasonable value range is set at 97.20-108.00 CNY, maintaining the "Outperform the Market" rating [6][7]. Financial Performance - In the first half of 2024, the company achieved operating revenue of 1.39 billion CNY, a year-on-year decrease of 5.5%, and a net profit attributable to the parent company of 360 million CNY, down 21.0% year-on-year. The earnings per share (EPS) is 0.68 CNY, with a return on equity (ROE) of 5.25% [6][7]. - The average daily trading volume of stock funds in the market decreased by 6.4% year-on-year to 961.6 billion CNY, impacting the demand for financial information services [6]. Revenue Breakdown - The revenue from value-added telecommunications services was 769 million CNY, down 10.9% year-on-year; software sales and maintenance revenue was 103 million CNY, down 7.2%; fund sales and other income was 170 million CNY, down 4.9%; while advertising and internet promotion revenue increased by 9.4% to 350 million CNY [6][10]. R&D Investment - The company's R&D expenses in the first half of 2024 were 590 million CNY, an increase of 5.1% year-on-year, accounting for 42.6% of operating revenue, up 4.3 percentage points year-on-year. The company has made significant progress in AI technology research and development, with numerous achievements in various technical fields [6][7]. Cost and Profitability - The total cost rate for the first half of 2024 was 73.9%, an increase of 6.6 percentage points year-on-year. The operating costs, selling expenses, and management expenses increased by 2.3%, 8.8%, and 13.3% year-on-year, respectively [6][11]. Future Earnings Forecast - The projected net profits for 2024E-2026E are 1.16 billion CNY, 1.34 billion CNY, and 1.49 billion CNY, reflecting year-on-year changes of -17.1%, +14.9%, and +11.3%, respectively. The corresponding EPS for these years is expected to be 2.16 CNY, 2.49 CNY, and 2.77 CNY [7][11].

Investment Rating - The investment rating for the company is "Outperform the Market" and is maintained [1] Core Views - The report indicates that the silicon material prices have reached a bottom, and the pressure from impairment losses is expected to significantly decrease. The company has adjusted its production load to better control costs and stabilize product prices [4][3] - The company achieved a revenue of 4.584 billion yuan in the first half of 2024, a year-on-year decrease of 50.84%, with a net profit attributable to the parent company of -670 million yuan. In Q2 2024, revenue was 1.602 billion yuan, down 64.14%, with a net profit of -1 billion yuan [3][5] Summary by Sections Financial Performance - In H1 2024, the company reported a revenue of 4.584 billion yuan, down 50.84% year-on-year, and a net profit of -670 million yuan. Q2 2024 saw a revenue of 1.602 billion yuan, a 64.14% decline, with a net profit of -1 billion yuan and impairment losses of 781 million yuan due to inventory price declines [3][5] - The company’s cash investment was 9.912 billion yuan, and the balance of construction in progress increased to 9.565 billion yuan due to the completion of a 100,000-ton high-purity polysilicon project in Inner Mongolia [3] Production and Market Strategy - The company has adjusted its production schedule and is actively participating in controlling polysilicon supply. In H1 2024, the production of N-type monocrystalline silicon wafers exceeded 70%, with a total polysilicon output of 127,200 tons. The expected output for Q3 is between 43,000 to 46,000 tons, and the annual output forecast is adjusted to 210,000 to 220,000 tons [3][4] Price Trends and Market Outlook - The report suggests that polysilicon prices are stabilizing and entering a bottoming phase. As of late June 2024, polysilicon prices have begun to stabilize, with a notable increase in prices for N-type silicon wafers in August [4] - The report forecasts that from 2024 to 2026, the company's net asset per share will be 19.34, 19.65, and 20.46 yuan, respectively, with corresponding price-to-book ratios of 0.91, 0.89, and 0.86 [4][5]